IRCT2014112019840N1已完成2 期
assessment of prophylactic treatment with carvedilol in incidence of heart failure in patients with HER2 positive breast cancer receiving trastuzumab
Vice chancellor of research of Tehran university of medical scienses0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 no limit（—）
- 性别
- Female
入选标准
- •Inclusion:patients with HER2 positive breast cancer who are candidate for herceptin therapy
- •Exclusion: history of systolic heart failure (EF<50), history of anthracycline therapy,contraindications for beta blockers, history of coronary artery disease,symptoms of heart failure including orthopnea or PND or dyspnea on exertion
排除标准
- 未提供
研究者
相似试验
已完成
3 期
Assessment the effect of Carvedilol in preventing Heart failure in breast cancer patients.IRCT2017042433619N1Vice chancellor for research of Baqiyatallah University of Medical Sciences50
已完成
2 期
Study the preventive effect of Carvedilol therapy against Adriamycin-induced acute cardiotoxicity in breast cancer patients by measurement of myocardial deformation indexCongestive heart failureCondition 1: breast cancer. Condition 2: heart failure.Breast, unspecifiedIRCT2013093012924N1Vice chancellor for research, Mashhad University of Medical Sciences70
招募中
3 期
Effect of Carvedilol on Reducing Transtosomab Cardiac ComplicationsIRCT20190628044046N1Tehran University of Medical Sciences60
尚未招募
不适用
S1501 Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III”NeoplasmsKCT0004843ational Cancer Center20
招募中
3 期
Evaluation of the effect of carvedilol in patients with gastrointestinal cancerGastrointestinal cancers (Esophageal cancer, Gastric cancer, Pancreatic cancer, Colon cancer).Malignant neoplasm of stomachIRCT20200907048646N1Ardabil University of Medical Sciences60